Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-PSMA CAR NK cells
- Development stage
- Unknown
- Lead developer
- TABP EIC
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-PSMA CAR NK cells are genetically engineered natural killer (NK) cells that express a chimeric antigen receptor (CAR) targeting **prostate-specific membrane antigen (PSMA)**, which is highly expressed on prostate cancer cells. These cells are designed to recognize and kill PSMA-expressing tumor cells, especially in **castration-resistant prostate cancer (CRPC)**. The mechanism involves CAR-mediated antigen recognition, cytotoxicity, degranulation, and interferon-γ secretion, providing a targeted immunotherapeutic approach beneficial both as a monotherapy and in combination with other agents such as monoclonal antibodies (e.g., anti-PD-L1)[2][3][5][6]. Notably, these engineered NK cells provide a potential "off-the-shelf" universal cell therapy product[2]. Primary development has focused on the NK-92 cell line, a clinically validated, renewable NK cell source[2][3][5].
- Other names
- anti-PSMA CAR NK-92 cellsPSMA-targeted CAR NK cells
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on anti-PSMA CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-PSMA CAR NK cells.